

CONCLUSIONS

By comparing the PCS results of 1996 to 1998, 1999 to 2001, and 2003 to 2005 surveys, we can delineate changes in the process of care for prostate cancer patients treated with radiotherapy in Japan. Study data indicate a trend toward increasing early-stage disease and increasing proportions of patients treated with higher radiation doses with advanced equipments, suggesting that radical EBRT is gaining acceptance as a first-line treatment for prostate cancer in

Japan. Also, our results indicate that patterns of care for prostate cancer in Japan are becoming more similar to those in the United States. In the future, to optimize the delivery of radiotherapy, more advanced equipment and more FTE radiation oncologists are warranted. Also, repeat surveys and point-by-point comparisons of results from other countries, such as the United States, will demonstrate how EBRT for prostate cancer has been developed and optimized for patients in Japan.

REFERENCES

- Hanks GE, Coia LR, Curry J. Patterns of care studies: past, present and future. *Semin Radiat Oncol* 1997;7:97–100.
- Owen JB, Sedransk J, Pajak TF. National averages for process and outcome in radiation oncology: Methodology of the patterns of care study. *Semin Radiat Oncol* 1997;7:101–107.
- Tanisada K, Teshima T, Ohno Y, *et al.* Patterns of care study quantitative evaluation of the quality of radiotherapy in Japan. *Cancer* 2002;95:164–171.
- Teshima T. Patterns of care study in Japan. *Jpn J Clin Oncol* 2005;35:497–506.
- Nakamura K, Teshima T, Takahashi Y, *et al.* Radical radiotherapy for prostate cancer in Japan: A pattern of care study report. *Jpn J Clin Oncol* 2003;33:122–126.
- Nakamura K, Teshima T, Takahashi Y, *et al.* Radiotherapy for localized hormone-refractory prostate cancer in Japan. *Anticancer Res* 2004;24:3141–3145.
- Nakamura K, Ogawa K, Yamamoto T, *et al.* Trends in the practice of radiotherapy for localized prostate cancer in Japan: a preliminary patterns of care study report. *Jpn J Clin Oncol* 2003;33:527–532.
- Ogawa K, Nakamura K, Sasaki T, *et al.* Radical external beam radiotherapy for prostate cancer in Japan: Preliminary results of the 1999–2001 patterns of care process survey. *Jpn J Clin Oncol* 2004;34:29–36.
- Ogawa K, Nakamura K, Sasaki T, *et al.* Radical external beam radiotherapy for prostate cancer in Japan: preliminary results of the changing trends in the patterns of care process survey between 1996–1998 and 1999–2001. *Jpn J Clin Oncol* 2004;34:131–136.
- Ogawa K, Nakamura K, Onishi H, *et al.* Radical external beam radiotherapy for clinically localized prostate cancer in Japan: Changing trends in the patterns of care process survey between 1996–1998 and 1999–2001. *Anticancer Res* 2005;25:3507–3511.
- Ogawa K, Nakamura K, Onishi H, *et al.* Radical external beam radiotherapy for prostate cancer in Japan: Results of the 1999–2001 patterns of care process survey. *Jpn J Clin Oncol* 2006;36:40–45.
- Ogawa K, Nakamura K, Onishi H, *et al.* Influence of age on the pattern and outcome of external beam radiotherapy for clinically localized prostate cancer. *Anticancer Res* 2006;26:1319–1325.
- Ogawa K, Nakamura K, Onishi H, *et al.* Radical external beam radiotherapy for clinically localized prostate cancer in Japan: Differences in the patterns of care between Japan and the United States. *Anticancer Res* 2006;26:575–580.
- Sasaki T, Nakamura K, Ogawa K, *et al.* Postoperative radiotherapy for patients with prostate cancer in Japan: Changing trends in national practice between 1996–98 and 1999–2001: Patterns of care study for prostate cancer. *Jpn J Clin Oncol* 2006;36:649–654.
- Ogawa K, Nakamura K, Sasaki T, *et al.* Radical external beam radiotherapy for prostate cancer in Japan: Differences in the patterns of care among Japan, Germany, and the United States. *Radiat Med* 2008;26:57–62.
- Ogawa K, Nakamura K, Sasaki T, *et al.* External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of nadir prostate-specific antigen value within 12 months. *Int J Radiat Oncol Biol Phys* 2009;74:759–765.
- Sasaki T, Nakamura K, Ogawa K, *et al.* Radiotherapy for patients with localized hormone-refractory prostate cancer: results of the Patterns of Care Study in Japan. *BJU Int* 2009;104:1462–1466.
- Ogawa K, Nakamura K, Sasaki T, *et al.* Postoperative radiotherapy for localized prostate cancer: Clinical significance of nadir prostate-specific antigen value within 12 months. *Anticancer Res* 2009;29:4605–4613.
- Nakamura K, Ogawa K, Sasaki T, *et al.* Patterns of radiation treatment planning for localized prostate cancer in Japan: 2003–05 patterns of care study report. *Jpn J Clin Oncol* 2009;39:820–824.
- Yoshimi I, Mizuno S. Cancer Statistics Mortality trends of prostate cancer in Japan: 1960–2000. *Jpn J Clin Oncol* 2003;33:367.
- Schröder FH, Hugosson J, Roobol MJ, *et al.* Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med* 2009;360:1320–1328.
- Andriole GL, Crawford ED, Grubb RL III, *et al.* Mortality results from a randomized prostate-cancer screening trial. *N Engl J Med* 2009;360:1310–1319.
- D'Amico AV, Schultz D, Loffredo M, *et al.* Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. *JAMA* 2000;284:1280–1283.
- SAS procedure reference, version 6. 1st ed. Tokyo: SAS Institute Inc Japan; 1995.
- Zelevsky MJ, Moughan J, Owen J, *et al.* Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 patterns of care survey for prostate cancer. *Int J Radiat Oncol Biol Phys* 2004;59:1053–1061.
- Chuba PJ, Moughan J, Forman JD, *et al.* The 1989 patterns of care study for prostate cancer: Five-year outcomes. *Int J Radiat Oncol Biol Phys* 2001;50:325–334.
- Zietman A, Moughan J, Owen J, *et al.* The patterns of care survey of radiation therapy in localized prostate cancer: similarities between the practice nationally and in minority-rich areas. *Int J Radiat Oncol Biol Phys* 2001;50:75–80.
- Hanks GE, Teshima T, Pajak TF. 20 years of progress in radiation oncology: Prostate cancer. *Semin Radiat Oncol* 1997;7:114–120.
- Imai A, Teshima T, Ohno Y, *et al.* The future demand for and structural problems of Japanese radiotherapy. *Jpn J Clin Oncol* 2001;31:135–141.

30. Takahashi A, Yanase M, Masumori N, *et al.* External beam radiation monotherapy for localized or locally advanced prostate cancer. *Jpn J Clin Oncol* 2003;33:73–77.
31. Sasaki T, Nakamura K, Shioyama Y, *et al.* Efficacy of modest dose irradiation in combination with long-term endocrinal treatment for high-risk prostate cancer: A preliminary report. *Jpn J Clin Oncol* 2004;34:420–424.
32. Bolla M, Gonzalez D, Warde P, *et al.* Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. *N Engl J Med* 1997;337:295–300.
33. Pilepich MV, Caplan R, Byhardt RW, *et al.* Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group protocol 85-31. *J Clin Oncol* 1997;15:1013–1021.
34. Zietman AL. Radiation therapy or prostatectomy: an old conflict revisited in the PSA era; A radiation oncologist's viewpoint. *Semin Radiat Oncol* 1998;8:81–86.
35. Hanks GE, Schultheiss TE, Hanlon AL, *et al.* Optimization of conformal radiation treatment of prostate cancer: Report of a dose escalation study. *Int J Radiat Oncol Biol Phys* 1997;37:543–550.
36. Takara K. The origins and development of public health in Japan. In: Detels R, McEwen J, Omenn GS, editors. *The scope of public health. Oxford textbook of public health*. 3rd edition, vol. 1. New York: Oxford University Press; 1997. p. 55–72.



doi:10.1016/j.ijrobp.2011.01.029

CLINICAL INVESTIGATIONS

NATIONAL MEDICAL CARE SYSTEM MAY IMPEDE FOSTERING OF TRUE SPECIALIZATION OF RADIATION ONCOLOGISTS: STUDY BASED ON STRUCTURE SURVEY IN JAPAN

HODAKA NUMASAKI, PH.D.,* HITOSHI SHIBUYA, M.D.,[†] MASAMICHI NISHIO, M.D.,[‡] HIROSHI IKEDA, M.D.,[§]
 KENJI SEKIGUCHI, M.D.,^{||} NORIHIKO KAMIKONYA, M.D.,[¶] MASAHIKO KOIZUMI, M.D.,[#]
 MASAO TAGO, M.D.,** YUTAKA ANDO, M.D.,^{††} NOBUHIRO TSUKAMOTO, M.D.,^{‡‡}
 ATSURO TERAHARA, M.D.,^{§§} KATSUMASA NAKAMURA, M.D.,^{||||} MICHIHIDE MITSUMORI, M.D.,^{¶¶}
 TETSUO NISHIMURA, M.D.,^{###} MASATO HAREYAMA, M.D.,^{***} TERUKI TESHIMA, M.D.*, AND JAPANESE
 SOCIETY OF THERAPEUTIC RADIOLOGY AND ONCOLOGY DATABASE COMMITTEE

*Department of Medical Physics and Engineering, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; [†]Department of Radiology, Tokyo Medical and Dental University, Tokyo, Japan; [‡]Department of Radiology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan; [§]Department of Radiology, Sakai Municipal Hospital, Sakai, Osaka, Japan; ^{||}Department of Radiation Oncology, St. Luke's International Hospital, Tokyo, Japan; [¶]Department of Radiology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; [#]Oncology Center, Osaka University Hospital, Suita, Osaka, Japan; ^{**}Department of Radiology, Teikyo University School of Medicine University Hospital, Mizonokuchi, Kawasaki, Kanagawa, Japan; ^{††}Department of Medical Informatics, Heavy Ion Medical Center, National Institute of Radiological Sciences, Chiba, Japan; ^{‡‡}Department of Radiation Oncology, Saitama Medical University International Medical Center, Saitama, Japan; ^{§§}Department of Radiology, Toho University Omori Medical Center, Tokyo, Japan; ^{||||}Department of Radiology, Kyushu University Hospital at Beppu, Oita, Japan; ^{¶¶}Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine Kyoto University, Kyoto, Japan; ^{###}Division of Radiation Oncology, Shizuoka Cancer Center, Shizuoka, Japan; ^{***}Department of Radiology, Sapporo Medical University, Hokkaido, Japan

Purpose: To evaluate the actual work environment of radiation oncologists (ROs) in Japan in terms of working pattern, patient load, and quality of cancer care based on the relative time spent on patient care.

Methods and Materials: In 2008, the Japanese Society of Therapeutic Radiology and Oncology produced a questionnaire for a national structure survey of radiation oncology in 2007. Data for full-time ROs were crosschecked with data for part-time ROs by using their identification data. Data of 954 ROs were analyzed. The relative practice index for patients was calculated as the relative value of care time per patient on the basis of Japanese Blue Book guidelines (200 patients per RO).

Results: The working patterns of RO varied widely among facility categories. ROs working mainly at university hospitals treated 189.2 patients per year on average, with those working in university hospitals and their affiliated facilities treating 249.1 and those working in university hospitals only treating 144.0 patients per year on average. The corresponding data were 256.6 for cancer centers and 176.6 for other facilities. Geographically, the mean annual number of patients per RO per quarter was significantly associated with population size, varying from 143.1 to 203.4 ($p < 0.0001$). There were also significant differences in the average practice index for patients by ROs working mainly in university hospitals between those in main and affiliated facilities (1.07 vs 0.71; $p < 0.0001$).

Conclusions: ROs working in university hospitals and their affiliated facilities treated more patients than the other ROs. In terms of patient care time only, the quality of cancer care in affiliated facilities might be worse than that in university hospitals. Under the current national medical system, working patterns of ROs of academic facilities in Japan appear to be problematic for fostering true specialization of radiation oncologists. © 2011 Elsevier Inc.

Structure survey, Working pattern, Patient load, Quality of cancer care, Medical care system.

Reprint requests to: Teruki Teshima, M.D., Department of Medical Physics and Engineering, Osaka University Graduate School of Medicine 1-7, Yamadaoka, Suita, Osaka, 565-0871, Japan. Tel: +81-6-6879-2570; Fax: +81-6-6879-2570. E-mail: teshima@sahs.med.osaka-u.ac.jp

Supported by the Japanese Society of Therapeutic Radiology and Oncology (JASTRO) and Grants-in-Aid for Cancer Research (No. 18-4, 20S-5, and H19-3rd Term Cancer Control General-038) from the Ministry of Health, Labor and Welfare of Japan and by a Grant-

in-Aid for Scientific Research from the Japan Society for the Promotion of Sciences (No. 19390320 and 20591495).

Conflict of interest: none

Acknowledgments—We thank all radiation oncologists throughout Japan who participated in this survey for their efforts in providing us with valuable information to make this study possible.

Received Oct 15, 2010, and in revised form Dec 8, 2010. Accepted for publication Jan 12, 2011.

INTRODUCTION

The medical care systems of the United States and Japan are very different, which influences the personnel cost of medical staff. In radiation oncology, too, there is thus a major difference in personnel distribution between the United States and Japan. Most radiotherapy facilities in the United States are supported by full-time radiation oncologists (ROs), whereas the majority of radiotherapy facilities in Japan still rely on part-time ROs. Radiotherapy facilities with less than one full-time equivalent (FTE) RO on their staff still account for 56% nationwide (1). The Cancer Control Act was implemented in Japan in 2007 in response to patients' urgent petitions to the government (2). This act strongly advocates the promotion of radiotherapy (RT) and an increase in the number of ROs and medical physicists. However, a shortage of ROs still remains a major concern in Japan and will remain so for the foreseeable future.

The Japanese Society of Therapeutic Radiology and Oncology (JASTRO) has conducted national structure surveys of RT facilities in Japan every 2 years since 1990 (1, 3). The structure of radiation oncology in Japan has improved in terms of equipment and its functions in response to the increasing number of cancer patients who require RT.

In this study, we used the data of the JASTRO structure survey of 2007 to evaluate the actual work environment of radiation oncologists in Japan in terms of working pattern, patient load, and the quality of cancer care based on the relative time spent on patient care.

MATERIALS AND METHODS

Between March and December 2008, JASTRO carried out a national structure survey of radiation oncology in the form of a questionnaire in 2007 (1). The questionnaire consisted of questions about the number of treatment machines and modality by type, the number of personnel by job category, the number of patients by type, and the site. The response rate was 721 of 765 (94.2%) from all actual RT facilities in Japan.

Table 1 shows the overview of radiation oncology in Japan. University hospitals accounted for 15.8% of all RT facilities and had 40.0% of the total full-time ROs and treated 29.5% of all patients. The corresponding data were 4.0%, 7.8%, and 10.2% for cancer centers, and 80.2%, 52.2%, and 60.3% for other RT hospitals, respectively. "Full-time/part-time" indicates the employment pattern of RO. In Japan, even full-time ROs must work part-time in smaller facilities such as other RT hospitals. We considered these numbers to be inappropriate for accurate assessment of personnel. For this survey, we therefore collected FTE (40 h/week for radiation

oncology services only) data depending on hours worked in clinical RT of each RO. For example, if an RO works 3 days at a university hospital and 2 days at an affiliated hospital each week, FTE of the RO at the university hospital is 0.6 and at an affiliated hospital it is 0.4. The FTE of a facility that has three ROs with 0.8, 0.4, and 0.6 is calculated as 1.8 in total.

This survey collected the work situation data of a total of 1,007 full-time ROs and 534 part-time ROs. The data of full-time ROs were crosschecked with those of part-time ROs by using their identification data. Table 2 shows the result of crosschecking between data of full-time ROs and data of part-time ROs. In this study, data of 954 ROs were analyzed. Table 3 shows an overview of the analyzed data. In ROs working mainly in university hospitals, there are two ROs who worked at a maximum of six facilities (main facilities and five affiliated facilities) SAS 8.02 (SAS Institute Inc., Cary, NC) (4) was used for the statistical analysis, and the statistical significance was tested by means of the Student's *t*-test or analysis of variance.

The Japanese Blue Book guidelines (5, 6) for structure of radiation oncology in Japan based on Patterns of Care Study (PCS) data were used as the standard for comparison with the results of this study. PCS in Japan have been used since 1996 and have disclosed significant differences in the quality of RT by the type of facilities and their caseloads (7, 8). The standard guidelines for annual patient load per FTE RO have been set at 200 (warning level 300).

To evaluate quality of cancer care provided by ROs, the relative practice index for patients was calculated by the following expression.

$$\frac{\sum_{k=1}^n f_k}{\sum_{k=1}^n a_k} \times 200$$

in which *n* is the number of facilities that the RO works in (*n* = 1, 2, 3, ..., *k*), *f_k* is the FTE of the RO in facility *k*, and *a_k* is the annual number of patients per RO in facility *k*

Calculation method of coefficient "200:"

- 1) Number of weeks per year = (365–15)/7 = 50 weeks
 ※ Japan has 15 national holidays a year
- 2) 1.0 FTE = 40 h/week
- 3) Annual working hours of FTE 1.0 = 50 × 40 h = 2,000 h
- 4) Relative practice index for patients was normalized using the Blue Book guideline of 200 patients/FTE RO. For this guideline, care time per patient was set at 10 hours (2,000 h/200 patients).
- 5) Coefficient was 200 (2000/10).

RESULTS

Working patterns

Figure 1 shows working patterns of ROs working mainly in (a) university hospitals, (b) cancer centers, and (c) other

Table 1. Categorization of radiotherapy facilities in Japan

Facility category	Number of facilities	New patients	Total patients (new + repeat)	Full-time ROs		Part-time ROs	
				<i>n</i>	FTE	<i>n</i>	FTE
University hospital	114	50,351	60,555	403	293.0	70	21.6
Cancer center	29	16,794	20,968	78	73.7	14	2.5
Other radiotherapy hospital	578	103,084	123,564	526	351.8	450	83.7
Total	721	170,229	205,087	1,007	718.5	534	107.8

Abbreviations: RO = radiation oncologist; FTE = full-time equivalent (40 hours per week for radiation oncology services only).

Table 2. Connection between full-time and part-time RO data

Data of full-time ROs	
Total number	1,007
Number of full-time ROs excluded from this analysis*	53
Number of full-time ROs analyzed	954
Breakdown	
Number of ROs who worked as full-time staff at main facilities and as part-time staff at affiliated facilities	199
Number of ROs who conducted only radiotherapy-related work as full-time staff at individual facilities (FTE of the RO was 1.0)	275
Number of ROs who conducted radiotherapy-related and other work as full-time staff at individual facilities (FTE of the RO was less than 1.0)	480
Data of part-time ROs including duplicate ROs	
Total number	534
Number of ROs who worked as full-time staff at main facilities and as part-time staff at affiliated facilities (number of part-time ROs analyzed)	280
Number of ROs who worked as only part-time staff at the facilities (Number of part-time ROs excluded from this analysis)	254

Abbreviations: RO = radiation oncologist; FTE = full-time equivalent (40 hours per week for radiation oncology service only).

* Data of full-time ROs who worked at facilities with few patients were excluded, as were duplicated data of full-time ROs.

RT hospitals. The percentages of white parts in Figures 1 (a-c) were 17.4%, 5.0%, and 32.0%.

In university hospitals, the mean FTE RO for main facilities was 0.73 and for affiliated facilities it was 0.10. The corresponding figures were 0.94 and 0.01 for cancer centers, and 0.67 and 0.01 for other RT hospitals. For university hospitals, the ratio of ROs working only in main facilities was 16.4%, and the corresponding figures for cancer centers and other RT hospitals were 79.5% and 31.7%, respectively. The ratio of ROs working mainly in university hospitals and part-time in affiliated facilities was 44.5%. The corresponding data were 6.5% of ROs working primarily in cancer centers and 7.5% of ROs working mainly in other RT hospitals.

Patient loads

Figure 2(a) shows the patient load per RO working mainly in university hospitals, cancer centers, and other RT hospitals. Of ROs working primarily in university hospitals, 40.1% treated more than 200 patients per year. The corresponding ratios were 74.4% of ROs working primarily in cancer centers and 36.5% of those working mainly in other RT hospitals. The average number of patients treated by ROs working primarily in university hospitals was 189.2, with the corresponding figures being 256.6 patients in cancer centers and 176.6 in other RT hospitals. Figure 2(b) shows the patient load per RO working primarily in university hospitals. Of ROs working in university hospitals and affiliated facilities, 65.9% treated more than 200 patients per year, and the percentage was 19.3% of ROs working only in university hospitals. The former treated an average of 249.1 patients and the latter 144.0 patients per year.

The geographic patterns

Figure 3 shows the geographic distribution for 47 prefectures of the mean annual number of patients (new plus repeat) per RO arranged in order of increasing population by all prefectures in Japan (9). The average annual number of patients per RO per quarter ranged from 143.1 to 203.4, with significant differences among quarters ($p < 0.0001$). Figure 4 shows the top 10 prefectures with ROs who treated more than 200 patients per year in descending order: Tokyo, Osaka, Kanagawa, Hokkaido, Chiba, Aichi, Fukuoka, Hyogo, Miyagi, and Hiroshima.

Relative practice index for patients of ROs

Figure 5(a) shows the average relative practice index for patients of ROs in university hospitals and affiliated facilities (ROs working mainly in university hospitals). The average practice index of RO for patients was 1.07 at university hospitals and 0.71 at affiliated facilities for a statistically significant difference ($p < 0.0001$). Figure 5(b) shows the average relative practice index for patients of ROs working only in university hospitals, only in cancer centers, and only in other RT hospitals. The respective indices for the three categories were 1.26, 1.02, and 1.01. There were significant differences in the indices between university hospitals and cancer centers ($p = 0.0278$) and between university hospitals and other RT hospitals ($p < 0.0001$). The difference between cancer

Table 3. Overview of analyzed data

Main facility category	Number of full-time ROs working at main facilities	Number of part-time ROs working at affiliated facilities					Subtotal
		First*	Second*	Third*	Fourth*	Fifth*	
University hospital	372	160	59	14	4	2	239
Cancer center	78	5	0	0	0	0	5
Other radiotherapy hospital	504	34	2	0	0	0	36
Total	954	199	61	14	4	2	280

Abbreviation: RO = radiation oncologist.

* First: first affiliated facilities; second: second affiliated facilities; third: third affiliated facilities; fourth: fourth affiliated facilities; fifth: fifth affiliated facilities.




Fig. 1. Working patterns of ROs working mainly at (a) university hospitals, (b) cancer centers, and (c) other radiotherapy hospitals. Distribution of FTE ratio between main and affiliated facilities on each RO. Horizontal axis represents ROs in ascending order of own total FTE. Abbreviations: RO = radiation oncologist; FTE = full-time equivalent (40 hours per week for radiation oncology services only).

centers and other RT hospitals was not significant ($p = 0.9459$).

DISCUSSION

In the United States, most RT facilities are supported by full-time ROs, with an FTE of 1.0 for most ROs working at their own facilities. In Japan, on the other hand, more than a half of the facilities still rely on part-time ROs. The main reason of this discrepancy is a shortage of ROs. Between 2005 and 2007, the increase in the number of cancer




Fig. 2. Distribution of annual patient load/RO. (a) RO working mainly in university hospitals, cancer centers, and other radiotherapy hospitals. (b) RO working mainly in university hospitals. Horizontal axis represents ROs in ascending order of annual numbers of patients/RO. Q1: 0–25%, Q2: 26–50%, Q3: 51–75%, Q4: 76–100%. Abbreviations: RO = radiation oncologist; FTE = full-time equivalent (40 hours per week for radiation oncology services only).

patients requiring RT (7.3%) was higher than that in the number of FTE ROs (6.7%) (1). To make up for the shortage of ROs, most ROs in university hospitals must work part-time at affiliated hospitals, as is evident from the data shown in Figure 1. White parts of Figure 1 (a: 17.4%, b: 5.0% c: 32.0%) represent three types of data: (a) FTE data of ROs who were not provided in the survey questionnaire; (b) FTE data of part-time ROs whose identification data could not connect to those of full-time ROs; (c) FTE data of ROs working in nonradiation oncology services. In this survey, the data of type (a) and (b) were missing data and the data of type (c) were not collected. In other RT hospitals, the FTE of most ROs working in their own facilities is low and these ROs do not work part-time at other hospitals. There are two reasons for this. First, diagnosticians partly provide RT as ROs in their own hospitals and, second, other specialists (such as brain surgeons using gamma knife) partly function as ROs to provide RT. Because those facilities have few cancer patients, their patient load is less than that of university hospitals and cancer centers. These findings are evident from Figure 2(a). There was a major difference in the working patterns of ROs between university hospitals and cancer centers. FTE at their own facilities of most ROs working in university hospitals is less than 1.0, whereas that of most ROs working in cancer centers is 1.0,




Fig. 3. Geographic distribution for 47 prefectures of annual number of patients (new plus repeat) per RO in ascending order of prefectural population. Q1: 0–25%; Q2: 26–50%; Q3: 51–75%; Q4: 76–100%. Triangles represent average annual number of patients per RO for each prefecture. Blue circles show prefectural population. Horizontal broken lines indicate the average annual number of patients per RO per quarter. The shaded area represents the Japanese Blue Book guideline (150–200 patients per RO). Abbreviations: RO = radiation oncologist; FTE = full-time equivalent (40 hours per week for radiation oncology services only).

the same as in the United States and European countries. The shortage of ROs is not the only reason for the problems facing Japan. The pay system of ROs is another important reason. The salary of ROs in Japan is low because specialist medical fees for ROs are not covered by the Japanese health-care insurance system. Moreover, the salary of ROs in university hospitals is lower than in other types of facilities, so that most of these ROs must work part-time at affiliated hospitals to earn a living. One advantage of this system, however, is that advanced technology is introduced sooner and faster in affiliated hospitals.

The geographic patterns demonstrated significant differences in the patient load among prefectures, ranging from 83.2 to 321.4 patients per RO. There were more ROs in metropolitan than other areas. However, the number of ROs who had more than 200 patients (new plus repeat) was strongly associated with population (correlation coefficient: 0.94), so that the number of ROs in metropolitan area remained insufficient.

Gomi *et al.* reported that the survival rate of patients treated in academic RT facilities (university hospitals and cancer centers) was better than that of those treated in non-academic RT facilities in Japan (10). In this study, the proportion of facilities with part-time ROs in nonacademic RT facilities group was higher than that in academic RT facilities group. Part-time ROs have less care time per patient because they had a limit to working hours. On the basis of the presented evidence, the relative practice index for patients of ROs was calculated as one way to value quality of cancer care in this study. Concerning ROs working primarily in university hospitals, the average relative practice index for patients in affiliated facilities was less than that in main




Fig. 4. The top 10 prefectures with ROs who treated more than 200 patients in descending order: Tokyo, Osaka, Kanagawa, Hokkaido, Chiba, Aichi, Fukuoka, Hyogo, Miyagi, and Hiroshima. Abbreviation: RO = radiation oncologist.

facilities (university hospitals). Teshima *et al.* reported that academic RT facilities (university hospitals and cancer centers) had better equipments and manpower than nonacademic RT facilities (1). Therefore, ROs at large-scale university hospitals might be given sufficient support because large-scale university hospitals tend to have state-of-the-art equipment, practice leading-edge medical treatment techniques, and employ enough medical staff members. On the other hand, ROs of most affiliated facilities could provide only minimal cancer care because these facilities




Fig. 5. Relative practice index for patients of ROs. (a) Relative practice index for patients in university hospitals and affiliated hospitals (targeted ROs were working mainly in university hospitals and part-time in affiliated hospitals). (b) Relative practice index for patients in university hospitals, cancer centers, and other radiotherapy hospitals (targeted ROs were working only in university hospitals or cancer centers only or only in other radiotherapy hospitals). *The formula used for calculating relative practice index for patients is: $\frac{\sum_{k=1}^n f_k}{\sum_{k=1}^n a_k} \times 200$ n: number of facilities that the RO works in (n = 1, 2, 3, ..., k). f_k : FTE of the RO in facility k a_k : annual number of patients per RO in facility k. Abbreviations: RO = radiation oncologist; FTE = full-time equivalent (40 hours per week for radiation oncology services only).

tend to lack sufficient equipment and medical staff. Moreover, commuting between large-scale university hospitals and affiliated facilities resulted in a waste of time and in tiredness. Therefore, the quality of cancer care in affiliated facilities was worse than that in large-scale university hospitals. Although the annual number of patients per RO in cancer centers was higher than that in university hospitals and other RT hospitals, the average relative practice index for patients of ROs working only in cancer centers was lower than that for patients of ROs working only in university hospitals and equal to that for patients of ROs working only in other RT hospitals. It can thus be concluded that ROs in cancer centers worked efficiently.

The utilization rate of RT for new cancer patients in Japan is much lower than that in European countries and the United States. Because there are enough RT facilities distributed nationwide in Japan, an increase in the number of ROs would likely result in a spectacular improvement in the utilization rate of RT for new cancer patients. To increase the number of ROs, it is necessary to improve the work environment and conditions for radiation oncology in medical care facilities. One, feasible suggestion is for RT facilities to set up a new department of radiation oncology, so that the position of RO will be established at every such facility and the status of radiation oncology will improve as a result. In addition, the Cancer Control Act was approved in 2006 and the Basic Plan to Promote Cancer Control Program was approved by the Japanese Cabinet in 2007 to promote RT and education for ROs as well as other RT staff members. For the implementation of this law and plan, the availability of basic data of RO working conditions is essential. As a start, an education program called "Cancer Professional Training Plan" was started in April 2008 with the support of the Ministry of Education, Culture, Sports, Science and Technology.

Quality of cancer care was evaluated in this study with the aid of the relative practice index for patients. However, data concerning the processes and outcomes for cancer care using RT should be used for a more accurate evaluation of cancer care. In the United States, the National Cancer Data Base has been collecting data for cancer care. The data of National Cancer Data Base are useful for quality evaluation of cancer care (11, 12). Furthermore, PCS has been performed every 4 or 5 years since 1973 for a survey of the structure, processes, and outcomes of radiation oncology facilities (13). As PCS evolved into Quality Research in Radiation Oncology, peri-

odic assessments of radiation oncology have been conducted for evaluation of practice quality on a national basis. In Japan, the structure, processes and outcomes for cancer care using RT have been investigated by PCS every 4 years (7, 8). The Japanese PCS has evaluated the quality of cancer care with RT and provided evidence of the disparity in quality of RT among facilities (14–18). However, these data are insufficient because PCS is a two-stage cluster sampling survey. We have recently established a database system based on available radiation oncology data and the collection of cancer care data by means of this system is now in preparation.


This study based on the JASTRO structure survey has indicated that the current national medical care system may impede fostering of true specialization of radiation oncologists in Japan because it is suffering from systemic fatigue. Although private hospitals make much money by receiving fee-for-service reimbursement, public hospitals face major deficit problems. It is therefore necessary to redistribute the burden of medical costs. On the other hand, the Japanese medical care system is beneficial for patients and national finances. Japan has had a universal health insurance system since 1961. Even though the per-capita medical costs in Japan were less than half of those in the United States and the medical costs in relation to the gross domestic product in Japan were about half of those in the United States as of 2007 (19), the outcome of cancer treatment in Japan is the same or better than in the United States. It is therefore very important to collect at regular intervals detailed information about all cancer care facilities for evaluation of quality of care and medical care systems for cancer. In Japan, the JASTRO structure survey has collected structural data of radiation oncology. Furthermore, a database system for the collection of data regarding the processes and outcomes for cancer care has recently been established in Japan as well as an information infrastructure for evaluation of the quality of care in radiation oncology.

In conclusion, our survey found that ROs working in university hospitals and their affiliated facilities treated more patients than did other ROs. In terms of patient care time only, the quality of cancer care in affiliated facilities might be worse than that in university hospitals. Under the current national insurance system, working patterns of ROs in academic facilities in Japan tend to impede the fostering of true specialization of radiation oncologists.

REFERENCES

1. Teshima T, Numasaki H, Shibuya H, *et al.* Japanese structure survey of radiation oncology in 2007 based on institutional stratification of Patterns of Care Study. *Int J Radiat Oncol Biol Phys* 2010;78:1483–1493.
2. Maeda M. A review of cancer control strategy in Japan [in Japanese]. *J Natl Inst Public Health* 2008;57:304–307.
3. Teshima T, Numasaki H, Shibuya H, *et al.* Japanese structure survey of radiation oncology in 2005 based on institutional stratification of Patterns of Care Study. *Int J Radiat Oncol Biol Phys* 2008;2:144–152.
4. SAS Institute Inc. SAS User's Guide: Statistics. Cary, NC: SAS Institute Inc.; 1985.
5. Japanese PCS Working Group. Radiation oncology in multidisciplinary cancer therapy -Basic structure requirement for quality assurance of radiotherapy based on Patterns of Care Study in Japan. Ministry of Health, Labor and Welfare Cancer Research Grant Planned Research Study 14-6, 2005.
6. Japanese PCS Working Group. Radiation oncology in multidisciplinary cancer therapy -Basic structure requirement for quality assurance of radiotherapy based on Patterns of Care Study in

- Japan. Ministry of Health, Labor and Welfare Cancer Research Grant Planned Research Study 18-4, 2010.
7. Tanisada K, Teshima T, Ohno Y, *et al.* Patterns of Care Study quantitative evaluation of the quality of radiotherapy in Japan. *Cancer* 2002;95:164–171.
 8. Teshima T, Japanese PCS working group. Patterns of Care Study in Japan. *Jpn J Clin Oncol* 2005;35:497–506.
 9. Ministry of Internal Affairs and Communications, Statistics Bureau, Director-General for Policy Planning (Statistical Standards) & Statistical Research and Training Institute. Current population estimates as of October 1, 2007. Available from: www.stat.go.jp/english/data/jinsui/2007np/index.htm (accessed August 31, 2010).
 10. Gomi K, Oguchi M, Hirokawa Y, *et al.* Process and preliminary outcome of a patterns-of-care study of esophageal cancer in Japan: Patients treated with surgery and radiotherapy. *Int J Radiat Oncol Biol Phys* 2003;56:813–822.
 11. National Cancer Data Base. Available from: www.facs.org/cancer/ncdb/index.html (accessed June 30, 2010).
 12. Bilimoria KY, Stewart AK, Winchester DP, *et al.* The National Cancer Data Base: A powerful initiative to improve cancer care in the United States. *Ann Surg Oncol* 2008;15:683–690.
 13. Wilson JF, Owen JB. Quality research in radiation oncology: A self-improvement initiative 30 years ahead of its time? *J Am Coll Radiol* 2005;2:1001–1007.
 14. Yamauchi C, Mitsumori M, Sai H, *et al.* Patterns of care study of breast-conserving therapy in Japan: Comparison of the treatment process between 1995–1997 and 1999–2001 surveys. *Jpn J Clin Oncol* 2007;38:26–30.
 15. Toita T, Kodaira T, Uno T, *et al.* Patterns of radiotherapy practice for patients with cervical cancer (1999–2001): Patterns of Care Study in Japan. *Int J Radiat Oncol Biol Phys* 2008;70:788–794.
 16. Kenjo M, Uno T, Numasaki H, *et al.* Radiation therapy for esophageal cancer in Japan: Results of the Patterns of Care Study 1999–2001. *Int J Radiat Oncol Biol Phys* 2009;75:357–363.
 17. Uno T, Sumi M, Numasaki H, *et al.* Changes in patterns of care for limited-stage small cell lung cancer: Results of the 99-01 Patterns of Care Study—A nationwide survey in Japan. *Int J Radiat Oncol Biol Phys* 2008;71:414–419.
 18. Ogawa K, Nakamura K, Onishi H, *et al.* Japanese Patterns of Care Study Working Subgroup of Prostate cancer. External beam radiotherapy for clinically localized hormone-refractory prostate cancer: Clinical significance of nadir prostate-specific antigen value within 12 months. *Int J Radiat Oncol Biol Phys* 2009;74:759–765.
 19. OECD Health Data 2010. Paris: Organisation for Economic Co-Operation and Development; 2010.



Changing trend in the patterns of pretreatment diagnostic assessment for patients with cervical cancer in Japan

Natsuo Tomita ^{a,•}, Takafumi Toita ^b, Takeshi Kodaira ^a, Atsunori Shinoda ^c, Takashi Uno ^d,
Hodaka Numasaki ^e, Teruki Teshima ^e, Michihide Mitsumori ^f

^a Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

^b Department of Radiology, Graduate School of Medical Science, University of the Ryukyus, Okinawa, Japan

^c Department of Radiology, Shinshu University School of Medicine, Matsumoto, Japan

^d Department of Radiology, Graduate School of Medicine, Chiba University, Chiba, Japan

^e Department of Medical Physics and Engineering, Graduate School of Medicine, Osaka University, Suita, Japan

^f Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine Kyoto University, Kyoto, Japan

article info

Article history:

Received 22 June 2011

Accepted 26 August 2011

Available online 25 September 2011

Keywords:

Cervix

Radiotherapy

Pretreatment examination

abstract

Objective. Cancer staging systems should be responsive to the development of diagnostic tools. The International Federation of Gynecology and Obstetrics (FIGO) cervical cancer guidelines were modified in 2009 regarding the pretreatment assessment. We report the recent Japanese patterns of pretreatment workup for cervical cancer.

Methods. The Japanese Patterns of Care Study (PCS) working group analyzed the pretreatment diagnostic assessment data of 609 patients with cervical cancer treated with definitive radiotherapy in the two survey periods (1999–2001, 324; 2003–2005, 285) in Japan. Sixty-one of 640 institutions were selected for this survey using a stratified two-staged cluster sampling method.

Results. The use of optional examinations in the latest FIGO guidelines such as intravenous urography, cystoscopy, and proctoscopy was gradually decreasing. Surgical staging was rarely performed in either survey period. Computed tomography (CT) and magnetic resonance imaging (MRI) were widely used, and MRI has become increasingly prevalent even between the two survey periods. Primary lesion size and pelvic lymph node status was evaluated by CT/MRI for most patients in both surveys.

Conclusions. The use of CT/MRI that is encouraged in the latest FIGO staging guidelines already replaced intravenous urography, cystoscopy, and proctoscopy in Japan. Japanese patients received the potential benefit of CT/MRI because prognostic factors such as primary lesion size and pelvic lymph node status were evaluated by these modalities. The use of cystoscopy and proctoscopy should be continuously monitored in the future PCS survey because only CT/MRI could lead to the stage migration for patients on suspicion of bladder/rectum involvement on CT/MRI.

© 2011 Elsevier Inc. All rights reserved.

Introduction

Radiation therapy is established as an integral component of cervical cancer. Accurate understanding of the cancer's extent is necessary for appropriate radiation treatment planning. In the first place, precise cancer staging is essential to predict prognosis and make appropriate decision regarding the primary treatment. The International Federation of Gynecology and Obstetrics (FIGO) provided a global staging system for gynecologic cancers and made several modifications over time. The previous FIGO guidelines recommended that staging be based on physical examination, colposcopy, hysteroscopy,

lesion biopsy, cystoscopy, proctoscopy, intravenous urography, and X-ray examination of the chest and skeleton. Of these, findings of optional examinations such as lymphangiography, ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) are of value for planning therapy, but, because these are not generally available and the interpretation of results is variable, the findings of such studies should not be the basis for changing the clinical staging [1]. However, cancer staging systems should be based on, and updated according to, the latest available knowledge, implying that they should be responsive and adaptive to scientific developments [2]. Thus, the FIGO guidelines for cervical cancer were modified in January 2009. In the updated guidelines, radiological tumor volume and parametrial invasion should be recorded for those institutions with access to MRI/CT [3]. In addition, other investigations such as cystoscopy, proctoscopy, and intravenous urography were classified as optional and no longer mandatory [3].

• Corresponding author at: Department of Radiation Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusaku, Nagoya 464-8681, Japan. Fax: + 81 52 752 8390. E-mail address: ntomita@aichi-cc.jp (N. Tomita).

The Patterns of Care study (PCS) initially surveyed radiotherapy practice in the United States, and the structure, process, and outcomes of radiotherapy, as well as various problems in clinical practice, have been identified for cervical cancer [4,5]. The Japanese PCS began in 1996 and used the same methods [6]. To accurately evaluate the cancer stage and optimally treat Japanese cervical cancer patients, it is important to accurately delineate the intrinsic changes in the patterns of pretreatment workup for cervical cancer in Japan. We previously reported the care process patterns in pretreatment diagnostic assessment and staging for patients with cervical cancer treated in 1999–2001 [7]. We report here the corresponding results for 2003–2005, and the changes over the years in pretreatment work-up from the 1999–2001 to 2003–2005 survey periods are examined.

Methods and materials

Between 2006 and 2008, the Japanese PCS conducted a third national survey of patients with uterine cervical cancer treated with radiotherapy. Eligibility criteria for the survey were as follows: (1) carcinoma, (2) treated between January 2003 and December 2005, (3) no distant metastasis, (4) no prior or concurrent malignancy, (5) no gross para-aortic lymph node metastasis, and (6) no previous pelvic radiotherapy. Sixty-one of 640 institutions were selected for this survey using a stratified two-staged cluster sampling method. Before the random sampling, all institutions were classified into four groups. Institutions were classified by type and number of patients treated with radiotherapy. The Japanese PCS stratified institutions as follows: A1, academic institutions treating > 430 patients annually; A2, < 430 patients; B1, nonacademic institutions treating > 130 patients annually; B2, < 130 patients. Academic institutions included cancer center hospitals and university hospitals. Nonacademic institutions consisted of other facilities, such as national, prefectural, municipal, and private hospitals. The detailed criteria for stratification have been shown elsewhere [6]. The Japanese PCS surveyors performed on-site chart reviews at each participating facility using an originally developed database format for cervical cancer. Data collection included patient characteristics, details of the pretreatment workup, therapeutic information (e.g., radiotherapy, chemotherapy, and surgery), and treatment outcome. The Japanese PCS collected clinical data on 487 patients with uterine cervical cancer who were treated with radiotherapy from 61 institutions. In this study, 285 patients treated by radiotherapy without planned surgery were analyzed. These included 114 patients from A1 institutions, 87 patients from A2 institutions, 50 patients from B1 institutions, and 34 patients from B2 institutions. There were unknown and missing data in the tables because no valid data were found in the given resources.

The current study compared the pretreatment workup data of two Japanese PCS surveys with more than 600 patients (1999–2001, 324; 2003–2005, 285) with cervical cancer treated by radiotherapy with curative intent. The methods for the 1999–2001 Japanese PCS were the same as those for 2003–2005. Ratios were calculated without unknown or missing data. Statistical significance was tested using the chi-square test.

Results

Table 1 gives a comparison of the patient characteristics between the Japanese PCS 1999–2001 and 2003–2005 survey of cervical cancer patients treated with definitive radiotherapy. The ages of the analyzed cohort were significantly different in the 1999–2001 and 2003–2005 surveys ($p < 0.0001$). Histology and FIGO stage were not significantly different in the two survey periods.

Table 2 shows a comparison of the performance rates of diagnostic procedures with a certain rate of unknown or missing data between the 1999–2001 and 2003–2005 surveys. Most patients underwent a chest X-ray in both the 1999–2001 and 2003–2005 surveys, but the ratio of patients who underwent a chest X-ray significantly decreased

Table 1

Patient and tumor characteristics of patients with uterine cervical cancer treated with radiotherapy in each surveillance period.

Characteristics	No. of patients (%)		
	1999–2001 (n = 324)	2003–2005 (n = 285)	p
Age (years)			b0.0001
Range	26–100	25–95	
Median	71	67	
Histology			0.84
Squamous cell	300 (94%)	257 (92%)	
Adenocarcinoma	14 (4%)	14 (5%)	
Adenosquamous cell	4 (1%)	5 (2%)	
Other	2 (1%)	3 (1%)	
Unknown/missing	4 (•)	6 (•)	
FIGO stage			0.13
I	43 (14%)	27 (10%)	
II	102 (34%)	85 (30%)	
III	122 (40%)	132 (46%)	
IVA	35 (12%)	41 (14%)	
Unknown/missing	22 (•)	1 (•)	

Abbreviations: KPS: karnofsky performance status, FIGO: International Federation of Gynecology and Obstetrics.

Table 2

Pretreatment diagnostic procedure in the 1999–2001 and 2003–2005 survey periods.

Parameters	No. of patients (%)		
	1999–2001 (n = 324)	2003–2005 (n = 285)	p
Chest radiography			0.0002
Yes	241 (97%)	191 (88%)	
No	7 (3%)	25 (12%)	
Unknown/missing	76 (•)	69 (•)	
Intravenous urography			b0.0001
Yes	176 (72%)	86 (42%)	
No	68 (28%)	118 (58%)	
Unknown/missing	80 (•)	81 (•)	
Cystoscopy			0.0005
Yes	171 (74%)	123 (58%)	
No	60 (26%)	88 (42%)	
Unknown/missing	93 (•)	74 (•)	
Proctoscopy			0.027
Yes	108 (49%)	70 (34%)	
No	114 (51%)	134 (66%)	
Unknown/missing	102 (•)	81 (•)	
Barium enema			0.098
Yes	24 (11%)	14 (7%)	
No	193 (89%)	200 (93%)	
Unknown/missing	107 (•)	71 (•)	
Lymphangiography			0.71
Yes	3 (1%)	16 (9%)	
No	241 (99%)	171 (91%)	
Unknown/missing	80 (•)	98 (•)	
Surgical Staging			0.042
Yes	3 (1%)	10 (4%)	
No	257 (99%)	241 (96%)	
Unknown/missing	64 (•)	34 (•)	
Abdominal CT			0.053
Yes	258 (95%)	247 (98%)	
No	14 (5%)	5 (2%)	
Unknown/missing	52 (•)	33 (•)	
Pelvic CT			0.75
Yes	286 (97%)	255 (98%)	
No	8 (3%)	5 (2%)	
Unknown/missing	30 (•)	25 (•)	
Pelvic MRI			0.021
Yes	246 (86%)	234 (92%)	
No	39 (14%)	19 (8%)	
Unknown/missing	39 (•)	32 (•)	
FDG-PET			0.34
Yes	1 (0%)	0 (0%)	
No	254 (100%)	229 (100%)	
Unknown/missing	69 (•)	56 (•)	

Abbreviations: NA: not applicable.

between the two survey periods. Intravenous urography and cystoscopy were performed in approximately three-quarters of patients in the 1999–2001 survey, but only half of patients underwent these examinations in the 2003–2005 survey. The ratio of the patients who underwent proctoscopy also significantly decreased between the two survey periods. On the whole, the ratio of patients who underwent barium enema and lymphangiography was low in both the 1999–2001 and 2003–2005 surveys. Surgical staging was rarely performed in either survey. Almost all patients underwent abdominal and pelvic CT in both surveys, and the ratios were not significantly different in the two survey periods. The ratio of the patients who underwent pelvic MRI was already high in the 1999–2001 survey, but this ratio further increased significantly. The ratio of patients who underwent fluorodeoxyglucose positron emission tomography (FDG-PET) was 0% in both the 1999–2001 and 2003–2005 surveys.

Table 3 shows the performance status of the pretreatment evaluation for the primary lesion and pelvic lymph nodes with a certain rate of unknown or missing data. Primary lesion size was not evaluated for a certain percentage of patients in both the 1999–2001 and 2003–2005 surveys (11% and 15%, respectively). MRI was the most common modality for evaluating primary lesion size in both surveys. Median tumor size in the 2003–2005 survey was larger than that in the 1999–2001 survey. Especially, the ratio of tumors ≥ 60 mm increased between the two survey periods (13% to 24%). Pelvic nodal status was evaluated in almost all patients in both surveys. CT was most frequently used for the assessment of nodal status in both the 1999–2001 and 2003–2005 surveys (86% and 89%, respectively).

Discussion

The present study demonstrated that the use of optional examinations in the updated FIGO guidelines such as intravenous urography, cystoscopy, and proctoscopy is gradually decreasing in Japan, as well

as in the United States [4,8,9]. In the 2000–2002 US study on the pretreatment evaluation of patients with stage IIB or lower disease, the rates for performing intravenous urography, cystoscopy, and proctoscopy were only 1, 16, and 17%, respectively [9]. The National Comprehensive Cancer Network (NCCN) guideline also states that cystoscopy and proctoscopy are optional examinations for the pretreatment assessment of cervical cancer patients with a disease stage of IB2 or higher [10]. On the other hand, this study showed that these optional procedures were still often performed in the patients surveyed in Japan, although these are older data than the FIGO guidelines update. We think that, although cystoscopy and proctoscopy are not necessary for the pretreatment assessment of cervical cancer patients with a disease stage of IB1 or lower, those examinations with biopsy are required for patients with a disease stage of IB2 or higher on suspicion of bladder/rectum involvement on CT or MRI because only CT/MRI could lead to the stage migration. Surgical staging and lymphangiography were rarely performed in either survey period. Eifel et al. reported that lymph node status was assessed by lymphangiography in 13.6%, and surgical evaluation in 12.2%, in the 1996–1999 US PCS [5], and other studies revealed that the performance of lymphangiography has also been decreasing recently [4,8,9]. Lagasse et al. found lymphangiography to be unreliable as a basis for treatment decisions [11]. As for surgical staging, although the FIGO Committee agrees on its potential important benefits, cost-effectiveness is still a matter of investigation and debate in a disease that can be cured with the same efficacy by other non-surgical treatment modalities [2]. In addition, there is increased morbidity when surgical node dissection is combined with subsequent radiation therapy [12]. We think that these procedures were replaced by CT or MRI before we started to survey the pretreatment workup data on the Japanese PCS. We predict that the performance rates of intravenous urography, cystoscopy, and proctoscopy will also decrease further, to be replaced by CT or MRI as in the United States. The ratio of patients who underwent a chest X-ray decreased significantly between the two survey periods. We presume that chest X-rays may also be replaced with chest CT, which can be done with abdominal and pelvic CT at one time, although we did not examine the performance status of chest CT in the two surveys.

This study demonstrated that CT and MRI were routinely performed in Japan in both survey periods. In the 1990s, several researchers reported that tumor diameter, as assessed by MRI, significantly affected the outcome of cervical cancer patients treated with definitive radiotherapy [13,14]. Actually, the use of diagnostic imaging techniques to assess the size of the primary tumor is encouraged in the updated FIGO guidelines, and radiological tumor volume and parametrial invasion should be recorded for those institutions with access to MRI/CT [3]. This study showed that CT and MRI were already widely used before the revision of the FIGO guidelines in 2009, and pelvic MRI has become increasingly prevalent in Japanese clinical practice for cervical cancer even between the two survey periods. It is clear that the practice patterns of pretreatment workup in Japan and the USA are notable different than in areas which are less well developed. However, there is increasing availability of CT scanning in developing countries [9]. As CT and MRI techniques and training continue to develop, it is likely that accuracy for local staging will improve even further. Thus, we think that these cross-sectional diagnostic imaging will become more and more important to the pretreatment workup of cervical cancer. On the other hand, the use of CT or MRI is encouraged but still is not mandatory in the latest FIGO cervical cancer staging guidelines. As it stands now, it is important to record the staging method for each cervical cancer patient in any countries in order to avoid staging migration and to fairly compare treatment methods.

Primary lesion size was not evaluated for a certain percentage of patients in both surveys. As previously stated, since tumor size is an important prognostic factor for cervical cancer, it is necessary in clinical practice to evaluate the primary lesion size. MRI was the most common modality for evaluating primary lesion size in both surveys. On the other hand, a certain percentage of patients were had primary lesion size

Table 3
Pretreatment evaluation of the primary lesion and lymph node in the 1999–2001 and 2003–2005 survey periods.

Parameters	No. of patients (%)		
	1999–2001 (n = 324)	2003–2005 (n = 285)	p
Evaluation of primary lesion size			0.30
Yes	246 (89%)	202 (85%)	
No	29 (11%)	36 (15%)	
Evaluation method of primary lesion*			NA
Inspection and palpation	20 (8%)	20 (10%)	
CT	53 (22%)	81 (40%)	
MRI	152 (62%)	145 (72%)	
US	21 (8%)	65 (32%)	
Diameter of primary lesion (mm)			0.008
0–10	3 (1%)	0	
10–20	12 (6%)	10 (5%)	
20–30	33 (15%)	28 (15%)	
30–40	54 (25%)	25 (14%)	
40–50	52 (24%)	47 (25%)	
60 b	27 (13%)	45 (24%)	
Unknown/missing	110 ()	97 ()	
Median	45 (0–100)	50 (15–107)	
Evaluation of pelvic lymph node			0.024
Yes	271 (97%)	224 (90%)	
No	8 (3%)	24 (10%)	
Unknown/missing	45 ()	37 ()	
Evaluation method of pelvic lymph node*			NA
CT	233 (86%)	209 (89%)	
MRI	37 (14%)	136 (58%)	
US	0	7 (3%)	
Others	1 (0%)	3 (1%)	

Abbreviations: US: ultrasonography, NA: not applicable.

* Some patients overlap in the 2003–2005 column.

evaluated by a physician's inspection and palpation, which is the method recommended by FIGO for evaluating primary lesion size. However, we think that tumor size assessment by physical examination has the potential to estimate tumor size incorrectly. Especially in clinical trials, we should evaluate primary lesion size by MRI because of its accuracy. Pelvic lymph node status was not evaluated for a certain percentage of patients in both surveys. Although the evaluation of lymph node status is an important prognostic factor and is essential for radiation treatment planning, it is not included in the FIGO guidelines despite improvements in imaging techniques. We believe that physicians should evaluate the lymph node status at least in institutions with access to MRI/CT because cervical cancer has a poor prognosis in the presence of lymph node metastasis, and this is particularly evident in early stage disease [15]. We think that pelvic CT is unnecessary for the pretreatment assessment of a cervical cancer patient when her MRI covers the whole pelvis, but if not, pelvic CT is also necessary. In addition, abdominal CT is required for the assessment of para-aortic lymph node status in the case of positive pelvic lymph node or a locally-advanced stage.

PET was rarely performed for cervical cancer in the two survey periods in Japan, although it has dramatically increased in the evaluation of patients with malignant neoplasms since approximately 2000 in Japan. This was due to the Japanese health insurance plan which did not cover cervical cancer at that time. Several studies showed the accuracy of PET for the staging of cervical cancer [16]. The Japanese health insurance plan started to cover cervical cancer in 2006. Its application is expected to increase in Japan in the next Japanese PCS survey for cervical cancer.

The limitation of our study was that several cases reviewed in this survey had unknown or missing data. The tables for pretreatment diagnostic tests in this study probably do not provide an accurate estimate of overall usage. Nevertheless, our results demonstrate that the FIGO-recommended workup including cystoscopy and proctoscopy is steadily decreasing in Japan, and there is a large discrepancy between the FIGO-recommended workup with cystoscopy and proctoscopy, and the actual tests being used.

In summary, the Japanese PCS describes the changes over the years in pretreatment work-up from the 1999–2001 to 2003–2005 survey periods in Japan. This study revealed that the FIGO recommended workup is steadily decreasing in Japan, while CT and MRI have been routinely performed. Patterns of pretreatment workup should be continuously

monitored in order to avoid staging migration, to properly treat individual patients, and to fairly compare treatment methods.

Conflict of interest statement
None.

References

- [1] Quinn MA, Benedet JL, Odicino F, et al. Carcinoma of the cervix uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. *Int J Gynaecol Obstet* 2006;95(Suppl 1):S43–S103.
- [2] Odicino F, Pecorelli S, Zigliani L, et al. History of the FIGO cancer staging system. *Int J Gynaecol Obstet* 2008;101:205–10.
- [3] Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. *Int J Gynaecol Obstet* 2009;105:107–8.
- [4] Montana GS, Hanlon AL, Brickner TJ, et al. Carcinoma of the cervix: patterns of care studies: review of 1978, 1983, and 1988–1989 surveys. *Int J Radiat Oncol Biol Phys* 1995;32:1481–6.
- [5] Eifel PJ, Moughan J, Erickson B, et al. Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: a patterns of care study. *Int J Radiat Oncol Biol Phys* 2004;60:1144–53.
- [6] Teshima T. Patterns of care study in Japan. *Jpn J Clin Oncol* 2005;35:497–506.
- [7] Toita T, Kodaira T, Uno T, et al. Patterns of pretreatment diagnostic assessment and staging for patients with cervical cancer (1999–2001): patterns of care study in Japan. *Jpn J Clin Oncol* 2008;38:26–30.
- [8] Russell AH, Shingleton HM, Jones WB, et al. Diagnostic assessments in patients with invasive cancer of the cervix: a national patterns of care study of the American College of Surgeons. *Gynecol Oncol* 1996;63:159–65.
- [9] Amendola MA, Hricak H, Mitchell DG, et al. Utilization of diagnostic studies in the pretreatment evaluation of invasive cervical cancer in the United States: results of intergroup protocol ACRIN 6651/GOG 183. *J Clin Oncol* 2005;23:7454–9.
- [10] http://www.nccn.org/professionals/physician_gls/PDF/cervical.pdf 2009; volume 1.
- [11] Lagasse LD, Creasman WT, Shingleton HM, et al. Results and complications of operative staging in cervical cancer: experience of the Gynecologic Oncology Group. *Gynecol Oncol* 1980;9:90–8.
- [12] Scheidler J, Hricak H, Yu KK, Subak L, Segal MR. Radiological evaluation of lymph node metastases in patients with cervical cancer. A meta-analysis. *JAMA* 1997;278:1096–101.
- [13] Toita T, Kakinohana Y, Shinzato S, et al. Tumor diameter/volume and pelvic node status assessed by magnetic resonance imaging (MRI) for uterine cervical cancer treated with irradiation. *Int J Radiat Oncol Biol Phys* 1999;43:777–82.
- [14] Kodaira T, Fuwa N, Toita T, et al. Comparison of prognostic value of MRI and FIGO stage among patients with cervical carcinoma treated with radiotherapy. *Int J Radiat Oncol Biol Phys* 2003;56:769–77.
- [15] Aoki Y, Sasaki M, Watanabe M, et al. High-risk group in node-positive patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and post-operative pelvic irradiation. *Gynecol Oncol* 2000;77:305–9.
- [16] Grigsby PW, Siegel BA, Dehdashti F, et al. Posttherapy [¹⁸F] • urodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. *J Clin Oncol* 2004;22:2167–71.

Japanese Structure Survey of Radiation Oncology in 2007 with Special Reference to Designated Cancer Care Hospitals

Hodaka Numasaki¹, Hitoshi Shibuya², Masamichi Nishio³, Hiroshi Ikeda⁴, Kenji Sekiguchi⁵, Norihiko Kamikonya⁶, Masahiko Koizumi⁷, Masao Tago⁸, Yutaka Ando⁹, Nobuhiro Tsukamoto¹⁰, Atsuro Terahara¹¹, Katsumasa Nakamura¹², Michihide Mitsumori¹³, Tetsuo Nishimura¹⁴, Masato Hareyama¹⁵, Teruki Teshima¹ and Japanese Society of Therapeutic Radiology and Oncology Database Committee

Background and Purpose: The structure of radiation oncology in designated cancer care hospitals in Japan was investigated in terms of equipment, personnel, patient load, and geographic distribution. The effect of changes in the health care policy in Japan on radiotherapy structure was also examined.

Material and Methods: The Japanese Society of Therapeutic Radiology and Oncology surveyed the national structure of radiation oncology in 2007. The structures of 349 designated cancer care hospitals and 372 other radiotherapy facilities were compared.

Results: Respective findings for equipment and personnel at designated cancer care hospitals and other facilities included the following: linear accelerators/facility: 1.3 and 1.0; annual patients/linear accelerator: 296.5 and 175.0; and annual patient load/full-time equivalent radiation oncologist was 237.0 and 273.3, respectively. Geographically, the number of designated cancer care hospitals was associated with population size.

Conclusions: The structure of radiation oncology in Japan in terms of equipment, especially for designated cancer care hospitals, was as mature as that in European countries and the United States, even though the medical costs in relation to GDP in Japan are lower. There is still a shortage of manpower. The survey data proved to be important to fully understand the radiation oncology medical care system in Japan.

Key Words: Structure survey · Radiotherapy facility · Radiotherapy personnel · Radiotherapy equipment · Caseload · Medical care system

Strahlenther Onkol 2011;187:167–74

DOI 10.1007/s00066-010-2205-3

Japanische Strukturhebung zur Radioonkologie im Jahr 2007 unter besonderer Berücksichtigung von auf Krebsbehandlung spezialisierten Krankenhäusern

Hintergrund und Ziel: Es wurde die Struktur der Radioonkologie in auf Krebsbehandlung spezialisierten Krankenhäusern in Japan untersucht, und zwar im Hinblick auf Ausrüstung, Personal, Patientenaufkommen und geografische Verteilung. Ebenso

¹Department of Medical Physics and Engineering, Osaka University Graduate School of Medicine, Suita, Osaka, Japan,

²Department of Radiology, Tokyo Medical and Dental University, Tokyo, Japan,

³Department of Radiology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan,

⁴Department of Radiology, Sakai Municipal Hospital, Sakai, Osaka, Japan,

⁵Department of Radiation Oncology, St. Luke's International Hospital, Tokyo, Japan,

⁶Department of Radiology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan,

⁷Oncology Center, Osaka University Hospital, Suita, Osaka, Japan,

⁸Department of Radiology, Toho University Omori Medical Center, Tokyo, Japan,

⁹Department of Medical Informatics, Heavy Ion Medical Center, National Institute of Radiological Sciences, Chiba, Japan,

¹⁰Department of Radiation Oncology, Saitama Medical University International Medical Center, Saitama, Japan,

¹¹Department of Radiology, University of Tokyo Hospital, Tokyo, Japan,

¹²Department of Radiology, Kyushu University Hospital at Beppu, Oita, Japan,

¹³Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine Kyoto University, Kyoto, Japan,

¹⁴Division of Radiation Oncology, Shizuoka Cancer Center, Shizuoka, Japan,

¹⁵Department of Radiology, Sapporo Medical University, Hokkaido, Japan.

Received: August 13, 2010; accepted: October 7, 2010

Published Online: February 21, 2011

wurden die Auswirkungen von Veränderungen in der japanischen Gesundheitsfürsorge-Politik auf die Strahlentherapie-Struktur untersucht.

Material und Methodik: Die Japanische Gesellschaft für radiologische Therapie und Onkologie hat eine Erhebung zur nationalen Struktur der Strahlungs-onkologie im Jahr 2007 durchgeführt. Dabei wurden die Strukturen von 349 auf Krebsbehandlung spezialisierten Krankenhäusern und 372 anderen Strahlentherapie-Einrichtungen verglichen.

Ergebnisse: Die jeweiligen Ergebnisse in Bezug auf die Ausrüstung und das Personal in den auf Krebsbehandlung spezialisierten Krankenhäusern und anderen Einrichtungen waren: Linearbeschleuniger pro Einrichtung: 1,3 bzw. 1,0; jährliche Patientenzahl pro Linearbeschleuniger: 296,5 bzw. 175,0. Das jährliche Patientenaufkommen pro Vollzeitäquivalent-Radioonkologe betrug 237,0 bzw. 273,3. In geografischer Hinsicht stand die Anzahl der auf Krebsbehandlung spezialisierten Krankenhäuser in Relation zur Bevölkerungszahl.

Schlussfolgerung: Die Struktur der Radioonkologie in Japan war, was die Ausrüstung und insbesondere die auf Krebsbehandlung spezialisierten Krankenhäuser betrifft, ebenso ausgereift wie oder ausgereifter als in europäischen Ländern und in den Vereinigten Staaten, obwohl die medizinischen Kosten im Verhältnis zum BIP in Japan geringer sind. Es besteht weiterhin ein Mangel an Arbeitskräften. Die Erhebungsdaten haben sich als bedeutsam für ein umfassendes Verständnis des Radioonkologie-Krankenpflegesystems in Japan erwiesen.

Schlüsselwörter: Strukturerhebung · Strahlentherapie-Einrichtung · Strahlentherapie-Personal · Strahlentherapie-Ausrüstung · Patientenaufkommen · Medizinisches Versorgungssystem

Introduction

In developed countries in Europe, such as France, Germany, Italy, and the UK, as well as in the United States, the rates of radiotherapy use for cancer treatment are as high as 50% or more because there are sufficient radiotherapy facilities and personnel, such as radiation oncologists (ROs), medical physicists (MPs), and radiotherapy technologists (RTTs) [1, 2, 5, 11]. On the other hand, the current utilization rate of radiotherapy for new cancer patients in Japan is only 26.1% [19] and surgery is still predominant. In Japan, the Cancer Control Act has been implemented since 2007 in response to patients' urgent petitions to the government [8]. This law strongly advocates the promotion of radiotherapy. At the same time, the Ministry of Health, Labor, and Welfare began the accreditation of "designated cancer care hospitals (DCCHs)" with the aim of correcting regional differences in the quality of cancer care and strengthening cooperation between regional cancer care hospitals [3, 9, 13]. The Japanese Society of Therapeutic Radiology and Oncology (JASTRO) has conducted national structure surveys of radiotherapy facilities in Japan every 2 years since 1990 [18, 19]. The structure of radiation oncology in Japan has improved in terms of equipment and its functions in response to the increasing number of cancer patients who require radiotherapy.

In this study, the recent structure of radiation oncology in Japan was analyzed with special reference to DCCHs in terms of equipment, personnel, patient load, and geographic distribution. The effect of changes in the cancer care policy by the Japanese government on radiotherapy structure was also investigated. Furthermore, the medical care situation in Japan was compared with European countries and the United States.

Materials and Methods

JASTRO carried out a national structure survey of radiation oncology in 2007 by administering a questionnaire in 2008

[19]. The questionnaire consisted of items related to the number of treatment machines and modality by type, the number of personnel by job category, the number of patients by type, and the site. A response was received from 721 of 765 (94.2%) radiotherapy facilities in Japan. There were 377 DCCHs facilities by the end of fiscal year 2009. The surveys were not returned by 16 facilities, and 13 facilities did not have departments of radiotherapy at the time of the survey. Thus, the structures of 349 DCCHs and 372 other radiotherapy facilities were analyzed. In this survey, full-time equivalent (FTE) (40 hours/week only for radiation oncology service) data were surveyed depending on clinical working hours for radiotherapy of each staff. SAS® 8.02 (SAS Institute Inc., Cary, NC, USA) [12] was used for the statistical analysis. The statistical significance was tested by means of the X^2 test, Student's *t* test, or analysis of variance (ANOVA).

The Japanese Blue Book Guidelines (JBBG) [6, 7] were used for comparison with the results of this study. These guidelines pertain to the structure of radiation oncology in Japan based on Patterns of Care Study (PCS) [15, 17] data.

Results

Current Situation of Radiation Oncology

Table 1 shows the current situation of radiation oncology in Japan. The numbers of new patients and total patients in all radiotherapy facilities in Japan were estimated at approximately 181,000 ($170,229 \times 765/721$) and 218,000 ($205,087 \times 765/721$), respectively. For DCCHs, the corresponding numbers were approximately 117,000 ($112,101 \times 364/349$) and 141,000 ($135,383 \times 364/349$). The number of patients in DCCHs, thus, accounted for approximately 65% of the number of patients, both new and total ($117,000/181,000$ and $141,000/218,000$), in all radiotherapy facilities. The average numbers of new patients/facility were 321.2 for DCCHs and 156.3 for the other radiotherapy facilities, and for the average numbers of total

Table 1. Numbers of new patients and total patients (new plus repeat) requiring RT in designated cancer care hospitals and other hospitals.

Tabelle 1. Anzahl neuer Patienten und aller Patienten (neu plus wieder eingeliefert), die der Strahlentherapie bedürfen, in auf Krebsbehandlung spezialisierten Krankenhäusern und anderen Strahlentherapie-Einrichtungen.

	Designated cancer care hospitals	Others	Total
Facilities	349	372	721
New patients	112,101 ^a	58,128	170,229 ^b
Average no. new patients/facility	321.2	156.3	236.1
Total patients (new + repeat)	135,383 ^a	69,704	205,087 ^b
Average no. total patients/facility	387.9	187.4	284.4

^aSince the number of designated cancer care hospitals with RT was 364, the number of new patients in designated cancer care hospitals was estimated at approximately 117,000 (112,101 × 364/349), and the corresponding number of total patients (new plus repeat) at approximately 141,000 (135,383 × 364/349).

^bSince the number of radiotherapy facilities was 765 in 2007, the number of new patients was estimated at approximately 181,000 (170,229 × 765/721), and the corresponding number of total patients (new plus repeat) at approximately 218,000 (205,087 × 765/721).

patients/facility, the corresponding figures were 387.9 and 187.4, respectively.

Facility and Equipment Patterns and Patient Load/Linac

The radiotherapy equipment patterns and related functions in Japan are shown in Table 2. In DCCHs, 453 linacs and 103 ¹⁹²Ir RALSs were in current use, while the corresponding data for the other radiotherapy facilities were 354 and 20, respectively.

Table 2. Items of equipment, their function and patient load per unit of equipment in designated cancer care hospitals and other hospitals. Linac: Linear accelerator; IMRT: intensity-modulated radiotherapy; RALS: remote-controlled afterloading system; CT: computed tomography; 3D-CRT: three-dimensional conformal radiotherapy; RTP: radiotherapy planning.

Tabelle 2. Bestrahlungsgeräte, deren Funktion und Patientenaufkommen pro Gerät in auf Krebsbehandlung spezialisierten Krankenhäusern und anderen Strahlentherapie-Einrichtungen. Linac: Linear accelerator; IMRT: intensity-modulated radiotherapy; RALS: remote-controlled afterloading system; CT: computed tomography; 3D-CRT: three-dimensional conformal radiotherapy; RTP: radiotherapy planning.

	Designated cancer care hospitals (n = 349)		Comparison with 2005	Others (n = 372)		Comparison with 2005	Total (n = 721)	
	n	%	%	n	%	%	n	%
Linac	453	98.0 ^a	1.7 ^c	354	90.9 ^a	1.0 ^c	807	94.3 ^a
with dual energy function	339	74.8 ^b	1.7 ^c	200	56.5 ^b	0.2 ^c	539	66.8 ^b
with 3D-CRT function (MLC width ≤1.0 cm)	341	75.3 ^b	7.8 ^c	214	60.5 ^b	7.8 ^c	555	68.8 ^b
with IMRT function	165	36.4 ^b	6.4 ^c	70	19.8 ^b	5.9 ^c	235	29.1 ^b
Average no. linac/facility	1.3	-	-	1.0	-	-	1.1	-
Annual no. patients/linac	296.5 ^d	-	-	175.0 ^d	-	-	243.2 ^d	-
¹⁹² Ir RALS (current use)	103	29.5 ^a	-	20	5.4 ^a	-	127.0	17.1 ^a
X-ray simulator	246	69.3 ^a	-9.8 ^c	199	53.0 ^a	-8.7 ^c	445	60.9 ^a
CT simulator	277	75.1 ^a	11.8 ^c	220	56.7 ^a	8.3 ^c	497	65.6 ^a
RTP computer	630	96.8 ^a	0.5 ^c	440	93.8 ^a	3.4 ^c	1,070	95.3 ^a

^aPercentage of facilities which have this equipment.


^bPercentage calculated from the number of systems using this function and the total number of linac systems.

^cComparison with the data of 2005, calculated with the formula: *data of 2007 (%) - data of 2005 (%)*

^dPercentage calculated from the number of patients and the number of linac units. The facilities without linac were excluded from the calculation.

The rate of ownership of equipment at DCCHs was significantly higher than at the other radiotherapy facilities. As for the linac system in DCCHs, the dual-energy function was used in 339 units (74.8%), the three-dimensional conformal radiotherapy (3D-CRT) function in 341 (75.3%), and the IMRT function in 165 (36.4%). For the other radiotherapy facilities, the corresponding figures were 200 (56.5%), 214 (60.5%), and 70 (19.8%). The respective patient load/linac was 296.5 at DCCHs and 175.0 at the other radiotherapy facilities. The distribution of annual patient load/linac in Japan is shown in Figure 1a. The patient load at 20% of DCCHs and 6% of the other radiotherapy hospitals exceeded the JBBG warning level of 400 patients/linac. However, the average patient load/linac at the other facilities was below the guideline level. Compared with the data for 2005 [3], the rate of linac ownership and rate of installation of the various functions (dual-energy, 3DCRT, and IMRT function) in linac increased by 1.7%, 1.7%, 7.8%, and 6.4%, respectively at DCCHs. At the other radiotherapy facilities, these rates increased as well and the corresponding percentages were 1.7%, 0.2%, 7.8%, and 5.9%.

The patterns for radiotherapy planning systems (RTPs) and other equipment are shown in Table 2. X-ray simulators were installed in 69.3% of the DCCHs and in 53.0% of the other radiotherapy facilities, CT simulators in 75.7% and 56.7%, and RTPs in 96.8% and 93.8%, respectively. A noteworthy difference between the two types of facilities was found in the rates of X-ray simulator and CT simulator installation. Compared with the data for 2005 [3], X-ray simulator ownership decreased by 9.8%, while CT simulator and RTP ownership increased by 11.8% and 0.5%, respectively, at DCCHs, while



Figures 1a to 1c. a Distribution of annual patient load/linear accelerator at designated cancer care hospitals and other radiotherapy facilities. Horizontal axis represents facilities arranged in order of increase in annual number of patients/treatment equipment within facilities. b Distribution of annual patient load/FTE RO at designated cancer care hospitals and other radiotherapy facilities. Horizontal axis represents facilities arranged in order of increase in annual number of patients/FTE RO within facilities. The number of FTE RO for facilities with FTE <1 was calculated as FTE =1 to avoid overestimating patient load/FTE RO. c Distribution of annual patient load/RTT at designated cancer care hospitals and other radiotherapy hospitals. Horizontal axis represents facilities arranged in order of increase in annual number of patients/RTT within facilities. The number of FTE RTT for facilities with FTE <1 was calculated as FTE =1 to avoid overestimating patient load/FTE RTT. Q1: 0–25%; Q2: 26–50%; Q3: 51–75%; Q4: 76–100%.

Abbildungen 1a bis 1c. a) Verteilung des jährlichen Patientenaufkommens pro Linearbeschleuniger in auf Krebsbehandlung spezialisierten Krankenhäusern und anderen Strahlentherapie-Einrichtungen. Die horizontale Achse stellt die Einrichtungen dar, die nach der jährlichen Anzahl der Patienten pro Behandlungsgerät innerhalb der Einrichtungen in aufsteigender Reihenfolge angeordnet wurden. b) Verteilung des jährlichen Patientenaufkommens pro Vollzeitäquivalent-Radioonkologe in auf Krebsbehandlung spezialisierten Krankenhäusern und anderen Strahlentherapie-Einrichtungen. Die horizontale Achse stellt die Einrichtungen dar, die in aufsteigender Reihenfolge nach der jährlichen Anzahl der Patienten pro Vollzeitäquivalent-Radioonkologe innerhalb der Einrichtungen angeordnet wurden. Bei Einrichtungen mit Vollzeitäquivalent <1 wurde die Anzahl der Vollzeitäquivalent-Radioonkologen mit Vollzeitäquivalent =1 berechnet, um eine Überschätzung des Patientenaufkommens pro Vollzeitäquivalent-Radioonkologe zu vermeiden. c) Verteilung des jährlichen Patientenaufkommens pro Strahlentherapie-MTA in auf Krebsbehandlung spezialisierten Krankenhäusern und anderen Strahlentherapie-Krankenhäusern. Die horizontale Achse stellt die Einrichtungen dar, die in aufsteigender Reihenfolge nach der jährlichen Anzahl der Patienten pro Strahlentherapie-MTA innerhalb der Einrichtungen angeordnet wurden. Bei Einrichtungen mit Vollzeitäquivalent <1 wurde die Anzahl der Vollzeitäquivalent-Strahlentherapie-MTAs mit Vollzeitäquivalent =1 berechnet, um eine Überschätzung des Patientenaufkommens pro Vollzeitäquivalent-Strahlentherapie-MTA zu vermeiden. Q1: 0–25%; Q2: 26–50%; Q3: 51–75%; Q4: 76–100%.

at the other radiotherapy facilities X-ray simulator ownership decreased by 8.7% and CT simulator and RTP ownership increased by 8.3% and 3.4%, respectively.

Staffing Patterns and Patient Loads
Staffing patterns and patient loads in Japan are detailed in Table 3. The total numbers of FTE ROs were 571.3 for DCCHs

Table 3. Structure and personnel of designated cancer care hospitals and other hospitals. RT: radiotherapy; RO: radiation oncologist; FTE: full-time equivalent (40 hours/week only for RT practice); JASTRO: Japanese Society of Therapeutic Radiology and Oncology.

Table 3. Struktur und Personal von auf Krebsbehandlung spezialisierten Krankenhäusern und anderen Strahlentherapie-Einrichtungen. RT: radiotherapy; RO: radiation oncologist; FTE: full-time equivalent (40 hours/week only for RT practice); JASTRO: Japanese Society of Therapeutic Radiology and Oncology.

	Designated cancer care hospitals (n = 349)	Comparison with 2005 (%)	Others (n = 372)	Comparison with 2005 (%)	Total (n = 721)
Facilities with RT bed	171	-	110	-	281 (39.0)
Average no. RT bed/facility	4.3	-	2.0	-	3.1
Total (full + part-time) RO FTE	571.3	21.2 ^a	255.0	-15.9 ^a	826.3
Average no. FTE ROs/facility	1.6	14.3 ^a	0.7	-22.2 ^a	1.1
JASTRO-certified RO (full-time)	378	29.0 ^a	99	-25.6 ^a	477
Average no. JASTRO-certified ROs/facility	1.1	22.2 ^a	0.3	-25.0 ^a	0.7
Patient load/FTE RO	237.0	-5.8 ^a	273.3	14.1 [*]	248.2
Total (full + part-time) RT technologist FTE	962.2	-	671.9	-	1634.1
Average no. FTE RT technologists/facility	2.8	-	1.8	-	2.3
Patient load/FTE RT technologist	140.7	-	103.7	-	125.5
Total (full + part-time) medical physicist FTE	42.0	-	26.4	-	68.4
Total (full + part-time) RT nurse FTE	304.3	-	190.1	-	494.4

^aRate of increase compared with the data of 2005, calculated with the formula: $\frac{\text{data of 2007 (n)} - \text{data of 2005 (n)}}{\text{data of 2005 (n)}} \times 100 (\%)$

and 255.0 for the other radiotherapy facilities, while the corresponding average numbers of FTE ROs/facility were 1.6 and 0.7 and the numbers for the patient load/FTE RO 237.0 and 273.3. The distribution of annual patient load/FTE RO in Japan is illustrated in Figure 1b. More than 300 patients/RO (JBBG warning level) were treated in 22% of DCCHs and in 11% of the other facilities. In Figure 2a, the percentage of distribution of facilities by patient load/FTE RO is shown. The largest number of facilities featured a patient/FTE RO level in the 150–199 range for DCCHs and in the 100–149 range for the other radiotherapy facilities. The facilities which have less than 1 FTE RO still account for about 37.2% of DCCHs and 73.9% of the other radiotherapy facilities. In DCCHs, the average numbers of FTE ROs/facility and full-time JASTRO-certified ROs/facility increased by 14.3% and 22.2%, respectively, compared with 2005 data. In other radiotherapy facilities, however, those numbers decreased by 22.2% and 25.0%. The annual patient load/FTE RO decreased by 5.8% in DCCHs and increased by 14.1% in other radiotherapy facilities.

The total numbers of FTE RTTs were 962.2 for DCCHs and 671.9 for the other radiotherapy facilities, and the average numbers per facility were 2.8 and 1.8, respectively. The patient loads/FTE RTT were 140.7 and 103.7, respectively. The distribution of annual patient load/FTE RTT in Japan is shown in Figure 1c. More than 200 patients/RTT (JBBG warning level) were treated in 18% of DCCHs and in 8% of the other radiotherapy facilities, while Figure 2b shows the percentage of distribution of facilities by patient load/FTE RTT. The largest number of facilities featured a patient/FTE RTT level in the 100–119 range for DCCHs and in the 60–89 range for the other radiotherapy facilities. The total numbers of FTE MPs

and FTE radiotherapy nurses were 42.0 and 304.3 for DCCHs and 26.4 and 190.1 for the other radiotherapy facilities.


Geographic Patterns

Figure 3 shows the geographic distribution for 47 prefectures of a number of radiotherapy facilities arranged in order of increasing population for all prefectures in Japan [14]. There were significant differences in the average number of facilities per quarter for both all radiotherapy facilities and DCCHs (both: $p < 0.0001$). The numbers of all radiotherapy facilities and DCCHs were strongly associated with population size (respective correlation coefficients: 0.95 and 0.82).

Discussion

The utilization rate of radiotherapy for new cancer patients in Japan is less than a half of that for developed countries in Europe, such as France, Germany, Italy, and UK, as well as for the United States. Radiotherapy is expected to play an increasingly important role in Japan because the increase in the elderly population is the highest among developed countries. In Japan, the majority of facilities still rely on part-time ROs, especially in facilities other than DCCHs. The percentage distribution of facilities by patient load/RO in DCCHs proved to be largely similar to that of the United States in 1989 [16]. However, the facilities which have less than one FTE RO still account for about 37% of DCCHs in Japan. In European countries and the United States, on the other hand, most facilities have a full-time RO.

On a regional basis, the results of this study proved that DCCHs were in appropriate locations. In the 2005 survey [9], there were not enough DCCHs in some regions with a large population because many university facilities were not



Figures 2a and 2b. a Percentage of facilities by patient load/FTE RO for designated cancer care hospitals and other radiotherapy hospitals. Each bar represents an interval of 50 patients per FTE RO. The number of FTE ROs for facilities with FTE <1 was calculated as FTE =1 to avoid overestimating patient load/FTE RO. b Percentage of facilities by patient load/FTE RTT for designated cancer care hospitals and other radiotherapy hospitals. Each bar represents an interval of 20 patients per FTE staff. The number of FTE RTTs for facilities with FTE <1 was calculated as FTE =1 to avoid overestimating patient load/FTE RTT.

Abbildungen 2a und 2b. a Prozentsatz der Einrichtungen nach Patientenaufkommen pro Vollzeitäquivalent-Radioonkologe bei auf Krebsbehandlung spezialisierten Krankenhäusern und anderen Strahlentherapie-Krankenhäusern. Jeder Balken stellt ein Intervall von 50 Patienten pro Vollzeitäquivalent-Radioonkologe dar. Bei Einrichtungen mit Vollzeitäquivalent <1 wurde die Anzahl der Vollzeitäquivalent-Radioonkologe zu vermeiden. b Prozentsatz der Einrichtungen nach Patientenaufkommen pro Vollzeitäquivalent-Strahlentherapie-MTA bei auf Krebsbehandlung spezialisierten Krankenhäusern und anderen Strahlentherapie-Krankenhäusern. Jeder Balken stellt ein Intervall von 20 Patienten pro Vollzeitäquivalent-Mitarbeiter dar. Bei Einrichtungen mit Vollzeitäquivalent <1 wurde die Anzahl der Vollzeitäquivalent-Strahlentherapie-MTAs mit Vollzeitäquivalent =1 berechnet, um eine Überschätzung des Patientenaufkommens pro Vollzeitäquivalent-Strahlentherapie-MTA zu vermeiden.




Figure 3. Geographic distribution for 47 prefectures of the number of facilities arranged in order of increase in population. The dotted line shows the average number of facilities of the prefectures per quarter for all radiotherapy hospitals and the dashed line shows the average number for designated cancer care hospitals. Q1: 0–25%; Q2: 26–50%; Q3: 51–75%; Q4: 76–100%.

Abbildung 3. Geografische Verteilung der Anzahl der Einrichtungen in 47 Präfekturen, geordnet in aufsteigender Reihenfolge nach der Bevölkerungszahl. Die gepunktete Linie zeigt die durchschnittliche Anzahl der Einrichtungen der Präfekturen pro Viertel für alle Strahlentherapie-Krankenhäuser, und die gestrichelte Linie zeigt die durchschnittliche Anzahl für auf Krebsbehandlung spezialisierte Krankenhäuser. Q1: 0–25%; Q2: 26–50%; Q3: 51–75%; Q4: 76–100%.

certified as DCCHs by the Ministry of Health, Labor, and Welfare. The findings of the current survey show that some university facilities with many patients undergoing radiotherapy were certified as DCCHs. There are, thus, enough radiotherapy facilities in Japan with a nationwide distribution. The medical situation in Japan is susceptible to the effect of measures taken by local governments. Current radiotherapy potential in radiotherapy facilities other than DCCHs in Japan is underutilized because of personnel shortages.

In Japan, a new educational system is being developed to train specialists for cancer care, including ROs, MPs, medical oncologists, oncology nurses, and palliative care doctors. Although the numbers of ROs in DCCHs have increased, the numbers in the other radiotherapy hospitals have decreased. In Japan, many radiotherapy hospitals do not even have their own department of radiotherapy, while we are of the opinion that all radiotherapy hospitals, whether designated or not, need to have

Table 4. Structural features and personnel related to radiation oncology in developed countries and cost adapted from the Directory of Radiotherapy Centers of the International Atomic Energy Agency [4]. RO: radiation oncologist; GDP: Gross Domestic Product.

Tabelle 4. Strukturmerkmale und Personal im Bereich Radioonkologie in entwickelten Ländern und Kosten nach dem Strahlentherapiezentren-Verzeichnis der Internationalen Atomenergie-Organisation [4]. RO: radiation oncologist; GDP: Gross Domestic Product.

Country	RT facilities	ROs	Medical physicists	Population (million) ^a	Facilities/ Population	RO/ Population	Medical physicists/ Population	Medical costs of GDP (%) ^b
Germany	219	835	626	82.7	2.6	10.1	7.6	10.4
Italy	151	839	392	58.2	2.6	14.4	6.7	8.7
France	186	574	267	60.9	3.1	9.4	4.4	11.0
USA	2,514	2,943	1,879	303.9	8.3	9.7	6.2	16.0
Japan ^c	721	826.3 ^d	68.4 ^d	128.3	5.6	6.4	0.5	8.1

^aBased on Demographic Yearbook of United Nations [20].

^bBased on Demographic OECD Health Data 2009 [10].

^cBased on JASTRO structure survey 2007.

^dThese data are expressed as full-time equivalent. Most ROs or other oncologists at academic facilities work part-time at affiliated hospitals. Therefore, the total numbers of ROs does not reflect the actual structure of radiation oncology personnel in Japan.

their own department of radiotherapy. It was found that MPs work mainly in metropolitan areas or academic facilities, such as university hospitals or cancer centers. At present, there is no national license for MPs in Japan, but those with a master's degree in radiation technology or science and engineering can take the accreditation test for MPs administered by the Japanese Board of Medical Physics (JBMP). The number of RTTs is more satisfactory than that of ROs and MPs, but RTTs are extremely busy because they are also partially act as MPs in Japan. The average number of radiotherapy staff members in DCCHs was greater than that in the other radiotherapy hospitals. Equipment ownership in the other radiotherapy facilities increased compared with 2005, being more firmly established in DCCHs than in the other radiotherapy hospitals. Therefore, the accreditation of DCCHs is closely correlated with the maturity of the radiation oncology structure. Further accreditation of DCCHs by the Ministry of Health, Labor, and Welfare would be a move in the right direction for the geographical consolidation of radiotherapy facilities in Japan.

The Directory of Radiotherapy Centers of the International Atomic Energy Agency has disclosed the member countries' data for the structure of radiation oncology [4]. Table 4 shows the data for the structure of radiation oncology in Japan, Germany, Italy, France, and the United States. The numbers of ROs and MPs per million population in Japan (6.4 and 0.5) are smaller than in France (9.4 and 4.4), Germany (10.1 and 7.6), and Italy (14.4 and 6.7). However, the number of radiotherapy facilities per million population in Japan (5.6) is larger than in France (3.1), Germany (2.6), and Italy (2.6). As for the United States, the numbers of ROs, MPs, and radiotherapy facilities per million population (9.7, 6.2, and 8.3) are all larger than in Japan. These findings do not necessarily mean that the medical care system in Japan is inferior. Even though the medical costs in relation to GDP [10] in Japan are the lowest among the aforementioned five countries, the outcome of cancer treatment in Japan is the same or better than in the other developed countries.

To evaluate medical care systems for cancer at regular intervals, it is very important to collect detailed information for all cancer care facilities. In Japan, JASTRO regularly surveys the structural information for all radiotherapy facilities and PCS has been conducted every 4 years to investigate the processes and outcomes of cancer care using radiotherapy. However, the collection of outcome information is insufficient. In the United States, a National Cancer Data Base was established and has been collecting the data for approximately 75% of cancer patients. This database is used as the quality indicator for improvements in the processes and outcomes of cancer care. We have recently established a Japanese National Cancer Database based on the radiotherapy data, and we are preparing to collect cancer care data with this system.

Conclusion

The structure of radiation oncology in DCCHs in Japan showed more maturity than that of other facilities in terms of equipment, functions, and staff. However, there is still a shortage of manpower. The survey data presented and discussed here are important and fundamental for clearly understanding the medical care system of radiation oncology in Japan. As the survey data make clear, a national policy is needed to solve the problem of the establishment of DCCHs and the shortage of manpower for cancer care.

Acknowledgments

This study was supported by the Japanese Society of Therapeutic Radiology and Oncology and Grants-in-Aid for Cancer Research (Nos. 18-4 and H19-3rd Term Cancer Control-General-038) from the Ministry of Health, Labor and Welfare of Japan and by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Sciences (Nos. 19390320 and 20591495). We would like to express our appreciation to all radiation oncologists and radiotherapy technologists throughout Japan who participated in this survey for providing us with valuable information to make this study possible.